Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) EPS (Weighted Average and Diluted) (2023 - 2025)

Historic EPS (Weighted Average and Diluted) for Lexaria Bioscience (LEXX) over the last 6 years, with Q4 2025 value amounting to -$0.07.

  • Lexaria Bioscience's EPS (Weighted Average and Diluted) rose 5625.0% to -$0.07 in Q4 2025 from the same period last year, while for Nov 2025 it was -$0.56, marking a year-over-year decrease of 1200.0%. This contributed to the annual value of $0.66 for FY2025, which is 4116.84% up from last year.
  • Lexaria Bioscience's EPS (Weighted Average and Diluted) amounted to -$0.07 in Q4 2025, which was up 5625.0% from $0.15 recorded in Q3 2025.
  • In the past 5 years, Lexaria Bioscience's EPS (Weighted Average and Diluted) ranged from a high of $0.18 in Q3 2023 and a low of -$0.21 during Q2 2025
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$0.04, with a median of -$0.1 in 2023.
  • Over the last 5 years, Lexaria Bioscience's EPS (Weighted Average and Diluted) had its largest YoY gain of 5625.0% in 2025, and its largest YoY loss of 15000.0% in 2025.
  • Over the past 3 years, Lexaria Bioscience's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.13 in 2023, then dropped by 23.08% to -$0.16 in 2024, then soared by 56.25% to -$0.07 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.07 for Q4 2025, versus $0.15 for Q3 2025 and -$0.21 for Q2 2025.